CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 83 enrolled
Drug / intervention
Tranexamic Aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03037515
NCT03037515Phase 4Completed
CompareCT.gov

A Randomized Controlled Trial of Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery

Henry Ford Health System·interventional·Posted Jan 31, 2017·Updated Feb 20, 2024

In Brief

A Phase 4 clinical trial evaluating Tranexamic Acid for Blood Loss, Surgical and Blood Loss Anemia. Completed, enrolled 83 participants across 1 site.

Detailed Summary

The purpose of this project is to compare the effectiveness of two different but well accepted routes of administration of tranexamic acid in order to reduce blood loss and need for transfusion in patients undergoing lumbar spine surgery. Specifically, this study seeks to identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlood Loss, Surgical, Blood Loss Anemia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 31, 2017
Enrollment StartFeb 15, 2017
Primary CompletionJun 15, 2018
Study CompletionJul 16, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.4 years ago

Interventions

Tranexamic Aciddrug

To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.